{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:08:22Z","timestamp":1786986502741,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.cgh.2014.01.021","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T18:26:42Z","timestamp":1390415202000},"page":"1443-1451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Risks of Serious Infection or Lymphoma With Anti\u2013Tumor Necrosis\u00a0Factor Therapy for Pediatric Inflammatory Bowel Disease: A\u00a0Systematic Review"],"prefix":"10.1016","volume":"12","author":[{"given":"Parambir S.","family":"Dulai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather B.","family":"Blunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C.","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2014.01.021_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bpg.2004.01.002","article-title":"Specificities of inflammatory bowel disease in childhood","volume":"18","author":"Griffiths","year":"2004","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ibd.21349","article-title":"Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends","volume":"17","author":"Benchimol","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib3","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/ibd.20919","article-title":"Strategies to improve quality of life in adolescents with inflammatory bowel disease","volume":"15","author":"Karwowski","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib5","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0016-5085(88)80072-6","article-title":"Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease","volume":"95","author":"Kanof","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib6","first-page":"165","article-title":"Longitudinal growth in children and adolescents with inflammatory bowel disease","volume":"18","author":"Hildebrand","year":"1994","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.01.021_bib10","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","article-title":"Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response","volume":"138","author":"Turner","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ibd.20069","article-title":"Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease","volume":"13","author":"Walters","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MPG.0b013e3181edd797","article-title":"Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction","volume":"52","author":"Malik","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib13","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.cgh.2008.07.010","article-title":"Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study","volume":"6","author":"Thayu","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.01.021_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal healing in inflammatory bowel diseases: a systematic review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2014.01.021_bib15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.01.021_bib16","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.01.021_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.20283","article-title":"Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease","volume":"14","author":"Siegel","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gutjnl-2011-300988","article-title":"Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options","volume":"61","author":"Siegel","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2014.01.021_bib19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/MPG.0b013e31824d1438","article-title":"Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary","volume":"54","author":"Veereman-Wauters","year":"2012","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.01.021_bib21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib22","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2014.01.021_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A\u00a0pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib24","unstructured":"SEER. Surveillance, Epidemiology, and End Results Database. Available at: http:\/\/seer.cancer.gov\/. Accessed March 22, 2013."},{"key":"10.1016\/j.cgh.2014.01.021_bib25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ibd.21844","article-title":"Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort","volume":"18","author":"Ashworth","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease","volume":"98","author":"Baldassano","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib28","first-page":"58","article-title":"Infliximab and pediatric stricturing Crohn's disease: a possible alternative to surgery? Experience of seven cases","volume":"75","author":"Gasparetto","year":"2012","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.cgh.2014.01.021_bib29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/ibd.20534","article-title":"Short-term response to adalimumab in childhood inflammatory bowel disease","volume":"14","author":"Noe","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib30","first-page":"307","article-title":"Infliximab as a novel therapy for pediatric ulcerative colitis","volume":"34","author":"Mamula","year":"2002","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib31","first-page":"298","article-title":"Infliximab in pediatric ulcerative colitis: two-year follow-up","volume":"38","author":"Mamula","year":"2004","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib32","first-page":"E112","article-title":"Single-dose of infliximab and short term response in resistant ulcerative colitis (CU)","volume":"50","author":"Romano","year":"2010","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10620-009-0791-7","article-title":"Adalimumab treatment in children with refractory Crohn's disease","volume":"55","author":"Rosenbach","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2014.01.021_bib34","first-page":"87","article-title":"Infliximab treatment time and the mucosal healing effect in pediatric patients with severe Crohn's disease\u2013own experience","volume":"7","author":"Czaja-Bulsa","year":"2012","journal-title":"Przeglad Gastroenterologiczny"},{"key":"10.1016\/j.cgh.2014.01.021_bib35","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/S1873-9946(13)60497-3","article-title":"Induction therapy with infliximab in children with moderate to severe ulcerative colitis","volume":"7","author":"Szychta","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2014.01.021_bib36","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/S1873-9946(13)60457-2","article-title":"Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry data","volume":"7","author":"Colletti","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2014.01.021_bib37","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1873-9946(13)60016-1","article-title":"Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data","volume":"7","author":"Baldassano","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2014.01.021_bib38","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/S1873-9946(13)60544-9","article-title":"Efficacy and safety of adalimumab (ADA) therapy in pediatric Crohn's disease (CD) patients who failed infliximab (IFX): a multicenter experience of the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition (SIGENP)","volume":"7","author":"Alvisi","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2014.01.021_bib39","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/S0016-5085(12)61420-6","article-title":"Efficacy of infliximab for Japanese paediatric Crohn's disease patients","volume":"142","author":"Yokoyama","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib40","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0016-5085(12)60139-5","article-title":"Long-term outcomes after institution of adalimumab therapy in pediatric Crohn disease","volume":"142","author":"Rosh","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib41","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0016-5085(12)60141-3","article-title":"Assessment of durability of infliximab maintenance therapy in children with Crohn's disease","volume":"142","author":"Pfefferkorn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib42","first-page":"26","article-title":"Maintenance therapy with infliximab for paediatric Crohn's disease: impact on clinical remission and mucosal healing in Polish paediatric patients with severe Crohn's disease","volume":"7","author":"Kierkus","year":"2012","journal-title":"Przeglad Gastroenterologiczny"},{"key":"10.1016\/j.cgh.2014.01.021_bib43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/MEG.0b013e32835159f2","article-title":"The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease","volume":"24","author":"Kierkus","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.01.021_bib44","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/00054725-201212001-00191","article-title":"Retrospective review of infliximab use in patients less than six years of age","volume":"18","author":"Christenson","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.crohns.2012.03.006","article-title":"Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease","volume":"7","author":"Assa","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2014.01.021_bib46","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/ibd.21885","article-title":"Concomitant therapy with methotrexate and anti-TNF-alpha in pediatric patients with refractory Crohn's colitis: a case series","volume":"18","author":"Absah","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib47","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.arcped.2011.05.022","article-title":"[Long-term outcome of infliximab therapy in pediatric Crohn disease]","volume":"18","author":"Wanty","year":"2011","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.cgh.2014.01.021_bib48","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2036.2011.04603.x","article-title":"A\u00a0British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease","volume":"33","author":"Russell","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.01.021_bib49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1651-2227.2010.01938.x","article-title":"Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing \u2018top-down\u2019 and \u2018step-up\u2019 strategies","volume":"100","author":"Kim","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.cgh.2014.01.021_bib50","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00054725-201112002-00012","article-title":"Infliximab therapy in pediatric patients 7 years of age and younger","volume":"17","author":"Kelsen","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1185\/03007995.2010.547575","article-title":"Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension","volume":"27","author":"Hyams","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2014.01.021_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2010.04507.x","article-title":"The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited","volume":"33","author":"De Bie","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.01.021_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MPG.0b013e3181bbf481","article-title":"Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use","volume":"50","author":"Tiemi","year":"2010","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib54","first-page":"425","article-title":"Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease","volume":"75","author":"De Greef","year":"2012","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.cgh.2014.01.021_bib55","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3748\/wjg.v16.i14.1776","article-title":"Efficacy of early treatment with infliximab in pediatric Crohn's disease","volume":"16","author":"Lee","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib56","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/ajg.2009.759","article-title":"Outcome following infliximab therapy in children with ulcerative colitis","volume":"105","author":"Hyams","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib57","first-page":"E36","article-title":"Clinical serious adverse events of infliximab in pediatric inflammatory bowel disease: a long-term retrospective study","volume":"48","author":"Roche","year":"2009","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib58","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2036.2009.03926.x","article-title":"Infliximab dependency in children with Crohn's disease","volume":"29","author":"Duricova","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.01.021_bib59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MPG.0b013e31815604cd","article-title":"12-month follow-up after successful infliximab therapy in pediatric Crohn disease","volume":"46","author":"Wynands","year":"2008","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ibd.20329","article-title":"Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort","volume":"14","author":"de Ridder","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib61","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1651-2227.2007.00042.x","article-title":"Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease","volume":"96","author":"Kolho","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.cgh.2014.01.021_bib62","first-page":"A444","article-title":"Infliximab as an induction agent versus ongoing maintenance therapy in mild-moderate pediatric Crohn's disease","volume":"132","author":"Feldman","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib63","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MPG.0b013e31802e98d4","article-title":"Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis","volume":"44","author":"Fanjiang","year":"2007","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib64","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s10620-007-8102-1","article-title":"Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease","volume":"52","author":"Afzal","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2014.01.021_bib65","first-page":"A656","article-title":"Open label experience with adalimumab in pediatric Crohn's disease patients who lost response or were intolerant to infliximab","volume":"130","author":"Deslandres","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00054725-200411000-00008","article-title":"Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease","volume":"10","author":"Lamireau","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib67","first-page":"46","article-title":"Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands","volume":"39","author":"de Ridder","year":"2004","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib68","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.dld.2003.12.014","article-title":"Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease","volume":"36","author":"Borrelli","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center","volume":"98","author":"Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib70","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","article-title":"Response to infliximab is related to disease duration in paediatric Crohn's disease","volume":"18","author":"Lionetti","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.01.021_bib71","first-page":"632","article-title":"A\u00a0prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease","volume":"36","author":"Cezard","year":"2003","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2014.01.021_bib72","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/S1590-8658(08)60535-6","article-title":"Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study","volume":"40","author":"Cucchiara","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib73","first-page":"A458","article-title":"Outcome of infliximab therapy in pediatric Crohn's disease: the first three years experience","volume":"126","author":"Sant'Anna","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib74","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/j.1572-0241.2000.03263.x","article-title":"Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease","volume":"95","author":"Kugathasan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1067\/mpd.2000.107161","article-title":"Use of infliximab in the treatment of Crohn's disease in children and adolescents","volume":"137","author":"Hyams","year":"2000","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cgh.2014.01.021_bib76","first-page":"342","article-title":"Biological agents in paediatric inflammatory bowel disease: a clinical observation study from Greece","volume":"73","author":"Chouliaras","year":"2010","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.cgh.2014.01.021_bib77","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/MCG.0b013e3181354417","article-title":"Infliximab for ulcerative colitis in children and adolescents","volume":"42","author":"McGinnis","year":"2008","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib78","first-page":"A580","article-title":"Immediate and long-term safety of infliximab in children with IBD","volume":"128","author":"Lee","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib79","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.MIB.0000160803.44449.a5","article-title":"Infliximab efficacy in pediatric ulcerative colitis","volume":"11","author":"Eidelwein","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib80","first-page":"166","article-title":"Infliximab is effective in acute but not chronic childhood ulcerative colitis","volume":"39","author":"Russell","year":"2004","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib81","first-page":"265","article-title":"Safety of infliximab treatment in pediatric patients with inflammatory bowel disease","volume":"39","author":"Friesen","year":"2004","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib82","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1345\/aph.10395","article-title":"Use of infliximab in pediatric patients with inflammatory bowel disease","volume":"35","author":"Serrano","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cgh.2014.01.021_bib83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MPG.0b013e318174e886","article-title":"Safety and efficacy of adalimumab in pediatric patients with Crohn disease","volume":"47","author":"Wyneski","year":"2008","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2014.01.021_bib84","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/ajg.2009.372","article-title":"Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease","volume":"104","author":"Viola","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib85","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/ibd.21615","article-title":"Long-term outcome of\u00a0treatment with infliximab in pediatric-onset Crohn's disease: a\u00a0population-based study","volume":"17","author":"Crombe","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib86","first-page":"344","article-title":"[Infliximab therapy for inflammatory bowel disease: seven years on]","volume":"67","author":"Segarra Canton","year":"2007","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.cgh.2014.01.021_bib87","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1016\/S0016-5085(11)62115-X","article-title":"Early use of infliximab in treatment-naive pediatric Crohns disease","volume":"140","author":"Olbjorn","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib88","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ibd.20845","article-title":"Long-term outcome of maintenance infliximab therapy in children with Crohn's disease","volume":"15","author":"Hyams","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.01.021_bib90","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(13)60617-4","article-title":"953 prolonged exposure to prednisone is decreasing in children with inflammatory bowel disease (IBD) during the last decade","volume":"144","author":"Sorbara","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.01.021_bib91","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2014.01.021_bib92","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1097\/MIB.0b013e318281325e","article-title":"Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study","volume":"19","author":"Afif","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.01.021_bib93","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2014.01.021_bib94","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2014.01.021_bib95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A\u00a0systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.01.021_bib96","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/ajg.2010.213","article-title":"Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality","volume":"105","author":"Kotlyar","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.01.021_bib97","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514001098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514001098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:15:24Z","timestamp":1761542124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356514001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1542356514001098"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2014.01.021","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks of Serious Infection or Lymphoma With Anti\u2013Tumor Necrosis\u00a0Factor Therapy for Pediatric Inflammatory Bowel Disease: A\u00a0Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2014.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}